Merck Patent Gmbh

Other

Vanita D Sood

Lars Toleikis

Christel Iffland

Qi An

Gang Hao

Mark J Cartwright

Christina Esdar

Olivier Leger

Sean D McKenna

Bjoern Hock

Horacio Gabriel Nastri

Christine Knuehl

Horacio G Nastri

Achim Doerner

Robin Lytle

Mark Cartwright

Xinyan Zhao

Carolin Sellmann

Johannes Yeh

David Nannemann

Sean D Mckenna

The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.

Monoclonal antibody directed to FGFR1

A heterodimeric bispecific immunoglobulin molecule includes a first Fab or scFv fragment which specifically binds to EGFR, and a second Fab or scFv fragment which specifically binds to c-MET, and an antibody hinge region, an antibody CH2 domain and an antibody CH3 domain including a hybrid protein-protein interaction interface domain. Each of the interaction interface domains is formed by an amino acid segment of the CH3 domain of a first member and an amino acid segment of the CH3 domain of a second member. The hybrid protein-protein interface domain of the first chain is interacting with the protein-protein-interface of the second chain by homodimerization of a corresponding amino acid segment of the same member of the immunoglobulin superfamily within interaction domains.

Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof

The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.

Anti-PD-L1 antibodies and uses thereof

Growing community of inventors

Somerville, MA, United States of America

Vanita D Sood